March 27, 2008 MEDIA CONTACT: Diane EganZOLL Medical Corporation+1 (978) email@example.com Kim AngelastroPublicis Consultants / PR+1 (212) firstname.lastname@example.org AutoPulse in the Cath Lab, LifeVest Wearable Defibrillator and STEMI Solutions to be Showcased at ACC '08 March 27, 2008—Chelmsford, MASS.—ZOLL Medical Corporation (Nasdaq GS: ZOLL), a manufacturer of resuscitation devices and related software solutions, today announced that it will display its range of clinical resuscitation products—including the AutoPulse® Non-invasive Cardiac Support Pump, the LifeVest® Wearable Defibrillator and STEMI solutions—in Booth #1041 at the 2008 American College of Cardiology Conference March 29-April 1 at McCormick place in Chicago. Nearly 30,000 cardiovascular professionals from around the world are expected to attend the 57th annual scientific sessions to learn about best practices and new innovations in cardiovascular science and education. The AutoPulse Non-invasive Cardiac Support Pump is an automated, portable device with an easy-to-use, load-distributing LifeBand® that squeezes the entire chest, improving blood flow to the heart and brain during sudden cardiac arrest (SCA). The AutoPulse has been shown to improve survival to discharge in a major study published in the Journal of the American Medical Association (JAMA)*. The only device of its kind, the AutoPulse delivers high-quality, uninterrupted chest compressions to maintain myocardial and cerebral perfusion, while freeing clinicians in the catheterization lab to perform procedures with optimal vascular access and minimal visual compromises. “In the cath lab, using AutoPulse means no compromises between PCI and other actions,” said Richard A. Packer, President and Chief Executive Officer of ZOLL. “This exclusive technology offers the additional benefit of safeguarding staff from X-ray exposure as well as maintaining the integrity of a sterile working environment.” LifeVest, the first and only wearable defibrillator, is designed to protect patients at high risk for SCA while they go about their normal lives, by being continuously connected to a wearable automatic defibrillator, weighing just 1.8 pounds. It is specifically approved by Medicare and other insurers for patients awaiting an ICD (implantable cardioverter defibrillator) or who have had one explanted due to an infection. It may be prescribed following a heart attack, before or after heart bypass surgery or stent placement, as well as for those with cardiomyopathy or congestive heart failure. More than 100 patients’ lives have been saved to date with this technology. ZOLL will also display the Company’s range of STEMI solutions that enable hospitals to rapidly transmit data from the field into the cath lab to assist clinicians in meeting ACC/AHA standards for door-to-balloon times. In addition to AutoPulse, LifeVest, and STEMI solutions, ZOLL will also display the ZOLL R Series™, a Code-Ready™ defibrillator that is simple, smart, and ready to use. It offers a OneStep™ system to simplify and speed up deployment of pacing and defibrillation therapy. It also offers smart tools to help clinicians improve CPR performance, which is important since more than half of in-hospital codes involve non-shockable rhythms and, in such cases, the only treatment is high-quality CPR with minimal interruptions. The R Series features both ZOLL’s Real CPR Help® and new patented See-Thru CPR™ technology. See-Thru CPR helps minimize interruptions in CPR—one of the key recommendations of the American Heart Association’s (AHA) Guidelines for Advanced Cardiac Life Support—by extracting CPR artifact and showing a “filtered” ECG on the defibrillator screen. It allows rescuers to see organized cardiac rhythm without stopping compressions. About ZOLL Medical Corporation ZOLL Medical Corporation is committed to developing technologies that help advance the practice of resuscitation. With products for pacing, defibrillation, circulation, ventilation, and fluid resuscitation, ZOLL provides a comprehensive set of technologies, including Real CPR Help® and See Thru CPR™, that help clinicians, EMS professionals, and lay rescuers resuscitate sudden cardiac arrest or trauma victims. ZOLL also designs and markets software that automates the documentation and management of both clinical and non-clinical information. ZOLL markets and sells its products in more than 140 countries. The Company has direct operations, distributor networks, and business partners throughout the U.S., Canada, Latin America, Europe, the Middle East and Africa, Asia, and Australia. 2008 marks the 25th anniversary of ZOLL’s resuscitation product development. For more information, visit www.zoll.com. Certain statements contained in this press release, including statements regarding the future business of the Company, and other statements contained herein regarding matters that are not historical facts, are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those factors discussed in the section entitled “Risk Factors” in the Company's Quarterly Report on Form 10-Q filed with the SEC on February 5, 2008. You should not place undue reliance on the forward-looking statements in this press release, and the Company disavows any obligation to update or supplement those statements in the event of any changes in the facts, circumstances, or expectations that underlie those statements. Copyright © 2008 ZOLL Medical Corporation. All rights reserved. 269 Mill Road, Chelmsford, MA 01824-4105. ZOLL, AutoPulse, LifeBand, and Real CPR Help are registered trademarks of ZOLL Medical Corporation. Code-Ready, One-Step, See-Thru CPR and R Series are trademarks of ZOLL Medical Corporation. All product names are the property of their respective owners. * Ong ME, Ornato JP et al. JAMA. 2006;295(22).